Table 1 |
||||
| Clinical and demographic characteristics of breast cancer patients treated with FEC/TX (n=66) and FEC/TX plus H (n=25) | ||||
| Characteristic | 66 patients treated with FEC/TX | 25 patients treated with FEC/TX plus H | ||
| pCR No. cases (%) | RD No. cases (%) | pCR No. cases (%) | RD No. cases (%) | |
| All patients | 25 (100) | 41 (100) | 12(100) | 13 (100) |
| Age in yrs | ||||
| Median (range) | 49 (34-69) | 49 (26- 67) | 50 (37-59) | 49 (39-64) |
| Histology | ||||
| Invasive ductal (IDC) | 24 (96.0) | 38 (92.7) | 12 (100.0) | 12 (92.3) |
| Invasive lobular (ILC) | 0 (0.0) | 1 (2.4) | 0 (0.0) | 0 (0.0) |
| Invasive mucinous (IMC) | 0(0.0) | 1 (2.4) | 0(0.0) | 0 (0.0) |
| NOS | 1 (4.0) | 1 (2.4) | 0 (0.0) | 1 (7.7) |
| Clinical tumor size at baseline | ||||
| T1 | 0 (0) | 1 (2.4) | 0 (0.0) | 0 (0.0) |
| T2 | 9 (36.0) | 14 (34.1) | 4 (33.3) | 7 (53.8) |
| T3 | 14 (56.0) | 23 (56.1) | 6 (50.0) | 4 (30.8) |
| T4 | 2 (8.0) | 3 (7.3) | 2 (16.7) | 2(15.4) |
| Clinical node status at baseline | ||||
| N0 | 8 (32.0) | 15 (36.6) | 2 (16.7) | 4 (30.8) |
| N1 | 12 (48.0) | 22 (53.7) | 7(58.3) | 4 (30.8) |
| N2 | 2 (8.0) | 2 (4.9) | 1 (8.3) | 4 (30.8) |
| N3 | 3 (12.0) | 1 (2.4) | 1 (8.3) | 0 (0.0) |
| Unkown | 1 (8.3) | 1 (7.7) | ||
| Histologic Grade | ||||
| 1 & 2 | 4 (16.0) | 10 (24.4) | 6 (50.0) | 3 (23.1) |
| 3 | 14 (56.0) | 26 (63.4) | 4 (33.3) | 9 (69.2) |
| Unknown | 7 (28.0) | 5 (12.2) | 2 (16.7) | 1 (7.7) |
| ER status | ||||
| Positive1 | 8 (32.0) | 20 (48.8) | 2 (1.7) | 8 (61.5) |
| Negative | 17 (68.0) | 20 (48.8) | 10 (76.9) | 5 (38.5) |
| Unknown | 0 (0.0) | 1 (2.4) | ||
| HER-2 status | ||||
| Positive 2 | 5 (20.0) | 5 (12.2) | 13 (100) | 12 (92.3) |
| Negative | 20 (80.0) | 33 (80.5) | 0 (0.0) | 1 (7.7) |
| Unknown | 0 (0.0) | 3 (7.3) | 0 (0.0) | 0 (0.0) |
1Cases where >10% of tumor cells stained positive for ER with immunohistochemistry were considered positive. 2Cases that showed either 3+ IHC staining or had gene copy number >2.0 were considered HER2-positive.
Shen et al. BMC Medical Genomics 2012 5:51 doi:10.1186/1755-8794-5-51
